CD8A and neoplasm: ASmA effectively reduces tumour cell proliferation and angiogenesis while enhancing the immune response by increasing the anti-tumour immunity and modulation of the TME as demonstrated by infiltration of CD8+ T cells, inhibition of Treg cells, and downregulating PD-L1 expression within the TME.